• Privacy policy
  • T&C’s
  • About Us
    • FAQ
    • Meet the Team
  • Contact us
TLE ONLINE SHOP!
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
SUPPORT THE LONDON ECONOMIC
NEWSLETTER
  • TLE
  • News
  • Politics
  • Business
  • Sport
  • Opinion
  • Elevenses
  • Entertainment
    • All Entertainment
    • Film
    • Lifestyle
      • Horoscopes
    • Lottery Results
      • Lotto
      • Thunderball
      • Set For Life
      • EuroMillions
  • Food
    • All Food
    • Recipes
  • Property
  • Travel
  • Tech/Auto
No Result
View All Result
The London Economic
No Result
View All Result
Home Prices and Markets

Sareum Holdings – Key ‘737 data coming up

Sareum’s investment case stands on two pillars: the development by licensee Sierra Oncology of the Chk1 inhibitor, SRA737; and the development and potential licensing of internally-generated TYK2 candidates for autoimmune disease and cancer…. Read more This year should see the first clinical data on SRA737, as well as further data from preclinical studies, that may […]

Edward Marten by Edward Marten
2019-03-22 12:44
in Prices and Markets
FacebookTwitterLinkedinEmailWhatsapp

Sareum’s investment case stands on two pillars: the development by licensee Sierra Oncology of the Chk1 inhibitor, SRA737; and the development and potential licensing of internally-generated TYK2 candidates for autoimmune disease and cancer…. Read more

This year should see the first clinical data on SRA737, as well as further data from preclinical studies, that may support a valuation uplift. Preclinical data on SRA737 in combination with low-dose gemcitabine and an anti-PD1 antibody in small cell lung cancer are due at the American Association for Cancer Research conference (AACR), on 29 March-3 April, and have the potential to surprise to the upside. Early clinical data on SRA737, and potentially on the competitor, prexasertib, are expected at the American Society of Clinical Oncology (ASCO), about two months later (abstracts revealed 15 May).

Several other developments have affected the investment case, most notably the proposed acquisition of Celgene by Bristol-Myers Squibb (BMS). BMS has featured its lead TYK2i prominently in presentations supporting the deal, which has increased attention on the drug class. Moreover, the acquisition, if completed, will also almost certainly mean that Celgene will not be able to exercise its option over Nimbus Therapeutics’ competing TYK2i.

QuotedData’s model suggests a current value for Sareum’s 27.5% economic interest in SRA737 at £20.3m and places an indicative value on its TYK2 assets of £8-16m. This representing a modest upgrade from its previous position and suggests an overall value for Sareum of £25-35m (0.87-1.14p/share), which offers up to 63% upside to the current share price.

RelatedPosts

Has Bitcoin bottomed out?

Five reasons why Bitcoin could be stuck in a temporary rut

Business Mogul Skeptical About Cryptocurrencies, Prefers NFTs

Nornickel’s GPF Rolls Out Instrument to Invest in Metals for Electric Car Industry

Subscribe to our Newsletter

View our  Privacy Policy and Terms & Conditions

Trending on TLE

  • All
  • trending
Abdollah

‘Rescue us’: Afghan teacher begs UK to help him escape Taliban

CHOMSKY: “If Corbyn had been elected, Britain would be pursuing a much more sane course”

What If We Got Rid Of Prisons?

More from TLE

The power of music: Keep on running

You can soon buy Prince Charles’ Bentley

Animal lovers horrified as boat owner repeatedly rams dinghy where Windo the seal has been sunbathing

Doing crosswords sharpens the brain

Forgotten Film Friday: The Steel Helmet

Thunderball Results for Saturday 4 September 2021 Tonight’s winning numbers

Film Review: In The Fade

Coronavirus: More than half a million people volunteer to help NHS

Bristol Post names and shames Greta Thunberg social media abusers

Parents want more ‘healthy competition’ in schools

About Us

TheLondonEconomic.com – Open, accessible and accountable news, sport, culture and lifestyle.

Read more

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.




No Result
View All Result
  • Home
  • News
  • Politics
  • Business
  • Sport
  • Entertainment
  • Lifestyle
  • Food
  • Travel
  • More…
    • Elevenses
    • Opinion
    • Property
    • Tech & Auto
  • About Us
    • Meet the Team
    • Privacy policy
  • Contact us

© 2019 thelondoneconomic.com - TLE, International House, 24 Holborn Viaduct, London EC1A 2BN. All Rights Reserved.